An Open-label, Randomized, 4-period, 4-treatment, Cross-over, Single-center, Single-dose Study to Assess the Relative Bioavailability of Ticagrelor in Different Formulations in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 04 Aug 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Abdominal aortic aneurysm; Acute coronary syndromes; Cardiovascular disorders; Community-acquired pneumonia; Coronary artery disease; Sickle cell anaemia; Stroke
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 01 Aug 2017 Status changed from active, no longer recruiting to completed.
- 20 Jun 2017 Planned End Date changed from 3 Jul 2017 to 11 Jul 2017.
- 20 Jun 2017 Planned primary completion date changed from 3 Jul 2017 to 11 Jul 2017.